Get started
Savara, Inc.Savara, Inc.Savara, Inc.

Savara, Inc.

No trades
No trades
OverviewFinancialsDocumentsNewsCommunityTechnicalsForecastsSeasonalsOptionsETFs
Full chart
Full chart

Compare with Savara, Inc.



Key stats


Market capitalization
‪1.19 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.56 USD
Net income (FY)
‪−118.84 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪106.86 M‬
Beta (1Y)
1.60

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Employees


Employees (FY)
70
Change (1Y)
+11+18.64%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−1.70 M‬ USD

Details


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Matthew Pauls
Website
savarapharma.com
Headquarters
Langhorne
Founded
1995
IPO date
Jun 25, 2001
ISIN
US8051111016
CUSIP
805111101
FIGI
BBG000MS0823
Identifiers
ISIN US8051111016
CFI code
ESVUFR
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs holding the stock


IWM
iShares Russell 2000 Index Fund
Weight0.03%
Market value‪22.86 M‬
XBI
State Street SPDR S&P Biotech ETF
Weight0.18%
Market value‪18.72 M‬
IWO
iShares Russell 2000 Growth Fund
Weight0.05%
Market value‪8.17 M‬
VTWO
Vanguard Russell 2000 ETF
Weight0.03%
Market value‪5.42 M‬
IBB
iShares Biotechnology ETF
Weight0.05%
Market value‪4.53 M‬
LFSC
F/m Emerald Life Sciences Innovation ETF
Weight3.01%
Market value‪3.90 M‬
IWC
iShares Microcap ETF
Weight0.20%
Market value‪3.03 M‬
JSML
Janus Henderson Small Cap Growth Alpha ETF
Weight0.63%
Market value‪2.39 M‬
FESM
Fidelity Enhanced Small Cap Core ETF
Weight0.03%
Market value‪2.22 M‬
ZPRR
State Street SPDR RUSSELL 2000 U.S. SMALL CAP UCITS ETF Accum Ptg USD
Weight0.03%
Market value‪1.87 M‬
VFMO
Vanguard U.S. Momentum Factor ETF
Weight0.09%
Market value‪1.74 M‬

Explore more ETFs 

Frequently asked questions


The current price of SVRA is 5.73 USD — it has decreased by −1.72% in the past 24 hours. Watch Savara, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Savara, Inc. stocks are traded under the ticker SVRA.
SVRA stock has risen by 5.33% compared to the previous week, the month change is a −8.90% fall, over the last year Savara, Inc. has showed a 117.05% increase.
We've gathered analysts' opinions on Savara, Inc. future price: according to them, SVRA price has a max estimate of 16.00 USD and a min estimate of 9.00 USD. Watch SVRA chart and read a more detailed Savara, Inc. stock forecast: see what analysts think of Savara, Inc. and suggest that you do with its stocks.
SVRA reached its all-time high on Apr 21, 2006 with the price of 9,405.60 USD, and its all-time low was 0.69 USD and was reached on Nov 14, 2019. View more price dynamics on SVRA chart.
See other stocks reaching their highest and lowest prices.
SVRA stock is 5.33% volatile and has beta coefficient of 1.60. Track Savara, Inc. stock price on the chart and check out the list of the most volatile stocks — is Savara, Inc. there?
Today Savara, Inc. has the market capitalization of ‪1.19 B‬, it has decreased by −5.66% over the last week.
Yes, you can track Savara, Inc. financials in yearly and quarterly reports right on TradingView.
Savara, Inc. is going to release the next earnings report on Aug 11, 2026. Keep track of upcoming events with our Earnings Calendar.
SVRA earnings for the last quarter are −0.15 USD per share, whereas the estimation was −0.14 USD resulting in a −11.11% surprise. The estimated earnings for the next quarter are −0.14 USD per share. See more details about Savara, Inc. earnings.
Savara, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
SVRA net income for the last quarter is ‪−37.28 M‬ USD, while the quarter before that showed ‪−32.24 M‬ USD of net income which accounts for 0.00% change. Track more Savara, Inc. financial stats to get the full picture.
No, SVRA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Aug 11, 2026, the company has 70 employees. See our rating of the largest employees — is Savara, Inc. on this list?
Like other stocks, SVRA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Savara, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Savara, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Savara, Inc. stock shows the buy signal. See more of Savara, Inc. technicals for a more comprehensive analysis.